Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

101. Apalutamide (Erleada) - non-metastatic castration-resistant prostate cancer (NM-CRPC)

Apalutamide (Erleada) - non-metastatic castration-resistant prostate cancer (NM-CRPC) Published 10 February 2020 Statement of advice SMC2268 apalutamide 60mg film-coated tablets (Erleada®) Janssen-Cilag Ltd 10 January 2020 ADVICE: in the absence of a submission from the holder of the marketing authorisation apalutamide (Erleada®) is not recommended for use within NHSScotland. Indication under review: In adult men for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC

2020 Scottish Medicines Consortium

102. Molecular Biomarkers in Localized Prostate Cancer

Molecular Biomarkers in Localized Prostate Cancer Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.02768 Journal of Clinical Oncology - published online before print December 12, 2019 PMID: Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline , MD 1 x Scott E. Eggener ; , MSc 2 (...) . were Expert Panel co-chairs. Abstract Section: PURPOSE This guideline provides recommendations for available tissue-based prostate cancer biomarkers geared toward patient selection for active surveillance, identification of clinically significant disease, choice of postprostatectomy adjuvant versus salvage radiotherapy, and to address emerging questions such as the relative value of tissue biomarkers compared with magnetic resonance imaging. METHODS An ASCO multidisciplinary Expert Panel

2020 American Society of Clinical Oncology Guidelines

103. Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. Full Text available with Trip Pro

Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. Guidelines endorsing vegetable-enriched diets to improve outcomes for prostate cancer survivors are based on expert opinion, preclinical studies, and observational data.To determine the effect of a behavioral intervention that increased vegetable intake on cancer progression in men with early-stage prostate cancer.The Men's (...) occurred from January 2013 to August 2017.Patients were randomized to a counseling behavioral intervention by telephone promoting consumption of 7 or more daily vegetable servings (MEAL intervention; n = 237) or a control group, which received written information about diet and prostate cancer (n = 241).The primary outcome was time to progression; progression was defined as PSA level of 10 ng/mL or greater, PSA doubling time of less than 3 years, or upgrading (defined as increase in tumor volume

2020 JAMA

104. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. Full Text available with Trip Pro

Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. Understanding adverse effects of contemporary treatment approaches for men with favorable-risk and unfavorable-risk localized prostate cancer could inform treatment selection.To compare functional outcomes associated with prostate cancer treatments over 5 years after treatment.Prospective, population (...) -based cohort study of 1386 men with favorable-risk (clinical stage cT1 to cT2bN0M0, prostate-specific antigen [PSA] ≤20 ng/mL, and Grade Group 1-2) prostate cancer and 619 men with unfavorable-risk (clinical stage cT2cN0M0, PSA of 20-50 ng/mL, or Grade Group 3-5) prostate cancer diagnosed in 2011 through 2012, accrued from 5 Surveillance, Epidemiology and End Results Program sites and a US prostate cancer registry, with surveys through September 2017.Treatment with active surveillance (n = 363

2020 JAMA

105. EANM Guideline/SNMMI Procedure Standard on [18F]Fluciclovine PET/CT for Prostate Cancer Imaging

EANM Guideline/SNMMI Procedure Standard on [18F]Fluciclovine PET/CT for Prostate Cancer Imaging [ 18 F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0 | SpringerLink Advertisement Search Search SpringerLink Search [ 18 F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0 , , , , , , , , , , , & ( 2019 ) 251 Accesses 4 Altmetric Abstract The aim of this guideline is to provide standards (...) for the recommendation, performance, interpretation, and reporting of [ 18 F]Fluciclovine PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of [ 18 F]Fluciclovine PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice. This is a preview of subscription content, to check access. Access options 2. Washburn LC, Sun TT, Byrd B, Hayes RL, Butler TA. 1-aminocyclobutane[11C] carboxylic

2020 Society of Nuclear Medicine and Molecular Imaging

106. Abiraterone acetate (Zytiga) - for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer

Abiraterone acetate (Zytiga) - for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer 1 Published 13 January 2020 1 SMC2215 abiraterone acetate 500mg film-coated tablets (Zytiga®) Janssen-Cilag Ltd 6 December 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following (...) a full submission assessed under the orphan medicine process abiraterone acetate (Zytiga ® ) is accepted for use within NHSScotland. Indication under review: abiraterone acetate with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer in adult men in combination with androgen deprivation therapy. Abiraterone acetate in combination with prednisone and androgen deprivation therapy demonstrated superiority over androgen deprivation

2020 Scottish Medicines Consortium

107. Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer Full Text available with Trip Pro

Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy (...) -Sensitive Prostate Cancer , , , , , , , , , Affiliations Expand Affiliations 1 University of Wisconsin, Madison, WI. 2 University of California, San Francisco, San Francisco, CA. 3 Johns Hopkins University, Baltimore, MD. PMID: 31644357 DOI: Item in Clipboard Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer Douglas G McNeel et al. J Clin Oncol . 2019 Show details J Clin Oncol Actions

2020 EvidenceUpdates

108. Darolutamide (Nubeqa) in nonmetastatic, castration-resistant prostate cancer (nmCRPC). Oncology Fact Sheet Nr. 2.

Darolutamide (Nubeqa) in nonmetastatic, castration-resistant prostate cancer (nmCRPC). Oncology Fact Sheet Nr. 2. Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC) - Repository of AIHTA GmbH English | Browse - - - Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC) Grössmann, N. (2020): Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC). Oncology Fact Sheet Nr. 2. Preview - Sie müssen

2020 Austrian Institute of Health Technology Assessment

109. The diagnostic value of miRNA-141 in prostate cancer: a systematic review and meta-analysis Full Text available with Trip Pro

The diagnostic value of miRNA-141 in prostate cancer: a systematic review and meta-analysis The diagnostic value of miRNA-141 in prostate cancer: a systematic review and meta-analysis The Editorial Office of APJBG The diagnostic value of miRNA-141 in prostate cancer: a systematic review and meta-analysis DOI: KeyWord : Author Institution Yun Ye Department of Laboratory Medicine, the First Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi, 710077, China. Xiaohua Yuan Department (...) . Hits : 451 Download times : 937 Abstract : MiR-141 has gradually demonstrated its value in the diagnosis of prostate cancer. However, the diagnostic parameters applied in previous studies were different. This systematic review was conducted to explore the diagnostic value of miR-141 in prostate cancer. A comprehensive search of related literature in PubMed, Medline, the Cochrane Library and Embase databases was performed. Seven studies were included which assessed the diagnostic value of miR-141

2020 Blood and Genomics

110. Abiraterone for treating metastatic prostate cancer

Abiraterone for treating metastatic prostate cancer ACE Technology Guidances newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT);metastatic castration-resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of ADT in whom chemotherapy is not yet clinically indicated; andmetastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease (...) indications for treating: newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT); metastatic castration-resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of ADT in whom chemotherapy is not yet clinically indicated; and metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

111. Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V

Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Apalutamide (Prostatakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 April 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-09 Apalutamide (...) (prostate cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-09 Version 1.0 Apalutamide (prostate cancer)) 24 April 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Apalutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 24 January 2019 Internal

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

112. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study (Abstract)

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study In the phase 3 TITAN study, the addition of apalutamide to androgen deprivation therapy (ADT) significantly improved the primary endpoints of overall survival and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer. We aimed to assess health-related quality of life (...) (HRQOL) in TITAN, including pain and fatigue.In this randomised, placebo-controlled, double-blind, phase 3 study, patients with metastatic castration-sensitive prostate cancer (defined as not receiving ADT at the time of metastatic disease progression) aged 18 years and older, receiving continuous ADT (selected at the investigator's discretion), and with an Eastern Cooperative Oncology Group performance status score of 0 or 1 were randomly assigned (1:1), using an interactive web response system

2019 EvidenceUpdates

113. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial Full Text available with Trip Pro

Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial Taxane-platinum combinations have shown promising activity in metastatic castration-resistant prostate cancers in single-group clinical studies but not in randomised trials. Distinct biological subsets of the disease might derive the greatest benefit from the addition of platinum. We aimed to determine whether adding carboplatin to cabazitaxel (...) would improve the outcomes of men with metastatic castration-resistant prostate cancer.We did a phase 1-2, open label, randomised study at two centres in men with progressive metastatic castration-resistant prostate cancer. In phase 1, patients received intravenous cabazitaxel 20-25 mg/m2 and intravenous carboplatin area under the curve (AUC) 3-4 mg/mL per min every 21 days. The maximum tolerated dose was defined as the highest dose cohort studied in which one of six or fewer patients experienced

2019 EvidenceUpdates

114. Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study Full Text available with Trip Pro

Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study Numerous pretreatment risk classification tools are available for prostate cancer. Which tool is best in predicting prostate cancer death is unclear.To systematically compare the prognostic performance of the most commonly used pretreatment risk stratification tools for prostate cancer.A nationwide cohort study was conducted, including 154 811 men (...) in Prostate Cancer data Base Sweden (PCBaSe) 4.0 diagnosed with nonmetastatic prostate cancer during 1998-2016 and followed through 2016.We compared the D'Amico, National Institute for Health and Care Excellence (NICE), European Association of Urology (EAU), Genito-Urinary Radiation Oncologists of Canada (GUROC), American Urological Association (AUA), National Comprehensive Cancer Network (NCCN), and Cambridge Prognostic Groups (CPG) risk group systems; the Cancer of the Prostate Risk Assessment (CAPRA

2019 EvidenceUpdates

115. Management of urethral stricture due to prostate cancer and colorectal cancer radiotherapy: a systematic review Full Text available with Trip Pro

Management of urethral stricture due to prostate cancer and colorectal cancer radiotherapy: a systematic review Bali Medical Journal Published by DiscoverSys Inc Open Access & Peer Reviewed Multidisciplinary Journal of Medical Sciences MENU > ORIGINAL ARTICLE DOI: Management of urethral stricture due to prostate cancer and colorectal cancer radiotherapy: a systematic review Sirin Salsabila , Muhammad Adi Satrio Lazuardi, Kharisma Ogit Rosandy Sirin Salsabila Faculty of Medicine, Universitas (...) Brawijaya, Malang, Indonesia. Email: Muhammad Adi Satrio Lazuardi Pasuruan General Hospital, Pasuruan, Indonesia Kharisma Ogit Rosandy Prima Husada Hospital, Malang, Indonesia  | |  | Online First: December 01, 2019 | ​ Salsabila, S., Lazuardi, M., Rosandy, K. 2019. Management of urethral stricture due to prostate cancer and colorectal cancer radiotherapy: a systematic review. Bali Medical Journal 8 (3): 788-792. DOI:10.15562/bmj.v8i3.1612 Background : Prostate and colorectal cancer

2019 Bali Medical Journal

116. Physical activity and prostate cancer: a systematic review Full Text available with Trip Pro

Physical activity and prostate cancer: a systematic review Physical activity and prostate cancer: a systematic review - MedCrave online Due to current COVID19 situation and as a measure of abundant precaution, our Member Services centre are operating with minimum staff eISSN: 2378-3176 Urology & Nephrology Open Access Journal Review Article Volume 7 Issue 5 Physical activity and prostate cancer: a systematic review Abdalla Ali Deb, 1 Verify Captcha × Regret for the inconvenience: we are taking (...) and Nephrology Cairo; Egypt Correspondence: Abdalla Ali Deb, Locum Consultant Urologist NHS- UK Received: October 06, 2019 | Published: October 30, 2019 Citation: Deb AA, Emmanuel O, Emara S, et al. Physical activity and prostate cancer: a systematic review. Urol Nephrol Open Access J . 2019;7(5):117-129. DOI: Abstract Numerous studies confirmed that planned exercise therapy is a possible adjunct strategy connected with significant improvements in symptom-related results including exercise tolerance as well

2019 Urology & Nephrology Open Access Journal

117. The Association between the Risk of Cardiovascular Disease and Androgen Deprivation Therapy in Patients with Prostate Cancer. A Meta-Analysis and systematic review. Full Text available with Trip Pro

The Association between the Risk of Cardiovascular Disease and Androgen Deprivation Therapy in Patients with Prostate Cancer. A Meta-Analysis and systematic review. The Association between the Risk of Cardiovascular Disease and Androgen Deprivation Therapy in Patients with Prostate Cancer. A Meta-Analysis and systematic review. | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research (...) Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article The Association between the Risk of Cardiovascular Disease and Androgen Deprivation Therapy in Patients with Prostate Cancer. A Meta-Analysis and systematic review. Zhen Liang, Jun Zhu, Xiaoxin Duo, Shangheng Shi, Yawei Xu

2019 Research Square

118. The Association between the Risk of Cardiovascular Disease and Androgen Deprivation Therapy in Patients with Prostate Cancer. A Meta-Analysis and systematic review. Full Text available with Trip Pro

The Association between the Risk of Cardiovascular Disease and Androgen Deprivation Therapy in Patients with Prostate Cancer. A Meta-Analysis and systematic review. The Association between the Risk of Cardiovascular Disease and Androgen Deprivation Therapy in Patients with Prostate Cancer. A Meta-Analysis and systematic review. | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research (...) Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article The Association between the Risk of Cardiovascular Disease and Androgen Deprivation Therapy in Patients with Prostate Cancer. A Meta-Analysis and systematic review. Zhen Liang, Jun Zhu, Xiaoxin Duo, Shangheng Shi, Yawei Xu

2019 Research Square

119. High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness (...) and Cost-Effectiveness High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated: February 14, 2019 Project Number: RC1070-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of high-dose-rate versus low-dose-rate brachytherapy for the treatment of prostate cancer? What

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

120. Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated (...) : February 22, 2019 Project Number: RC1069-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of hydrogel spacers for patients with prostate cancer? What is the cost-effectiveness of hydrogel spacers for patients with prostate cancer? Key Message Three systematic reviews, one randomized controlled trial (described within two eligible reports), seven cohort studies, two economic evaluations

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review